Published in final edited form as:

Mol Neurobiol. 2016 August ; 53(6): 4226–4237. doi:10.1007/s12035-015-9362-4.

Organotypic hippocampal slices as models for stroke and traumatic brain injury

Qian Li[#], Xiaoning Han[#], and Jian Wang

Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA

[#] These authors contributed equally to this work.

Abstract

Organotypic hippocampal slice cultures (OHSCs) have been used as a powerful *ex vivo* model for decades. They have been used successfully in studies of neuronal death, microglial activation, mossy fiber regeneration, neurogenesis, and drug screening. As a pre-animal experimental phase for physiologic and pathologic brain research, OHSC offers outcomes that are relatively closer to those of whole-animal studies than outcomes obtained from cell culture *in vitro*. At the same time, mechanisms can be studied more precisely in OHSCs than they can be *in vivo*. Here, we summarize stroke and traumatic brain injury research that has been carried out in OHSCs and review classic experimental applications of OHSCs and its limitations.

Keywords

Organotypic hippocampal slice cultures; stroke; traumatic brain injury

Introduction

Organotypic brain slice cultures are commonly used in brain disease research because they provide unique advantages over *in vivo* and *in vitro* platforms [1]. They largely preserve tissue structures, maintain neuronal activities and synapse circuitry, and replicate many aspects of the *in vivo* context. Additionally, the system is much simpler than an *in vivo* animal model and can be manipulated by overexpressing or knocking down genes. Thus, gene functions and pathways can be studied as easily as they can be in an *in vitro* system [1,2].

Slice systems have been successfully established from spinal cord (acute slice cultures) and various brain regions, including hippocampus, striatum, cortex, olfactory epithelium, thalamus, and cerebellum [1,3–9]. Slice cultures from hippocampus are the most commonly used to investigate the effects of drugs on neurons, microglia, and astrocytes and to assess neurogenesis. Organotypic hippocampal slice cultures (OHSCs) can be grown acutely or for

Address correspondence to: Jian Wang, MD, PhD, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross Bldg 370B, Baltimore, MD 21205 (Phone:443.287.5490; jwang79@jhmi.edu).

Compliance with ethical standards The authors declare no conflict of interest.

long periods (chronic slice culture). Chronic slice culture can represent brain development, including the patterns of gene regulation, protein expression, and synaptic activity of age-matched hippocampus *in vivo* [1,10–12]. Therefore, long-term hippocampal slice cultures are increasingly used as models for neurodegenerative disease, traumatic brain injury (TBI), and stroke, and as drug screening platforms to identify novel therapeutics. In figure 1, we summarize the disease models and pathophysiologic processes that can be studied with OHSCs and provide a schematic diagram showing a simple process for preparing chronic OHSCs.

OHSCs are usually prepared from rats or mice at postnatal days 3–9 (PND3–9) [1,13]. Brain tissue during this time has a high degree of plasticity and is resistant to mechanical trauma during the slice preparation. Rodents that are younger than PND3 are not suitable for long-term slice culture because the slices lose their morphological characteristics [14]. Slices from adult animals often undergo neuronal degeneration, although some researchers claim to have prepared slices from adult rodents and maintained them in culture for several weeks [1,15,16]. After the brain is removed from anesthetized animals and separated into two equal hemispheres, the tissues are chilled in ice-cold dissection medium consisting of Minimal Essential Medium (MEM), 24 mM HEPES, and 10 mM TRIS-HCl or Hanks' Balanced Salt Solution (HBSS), to help maintain viability and activity as much as possible [17]. Subsequently, a tissue chopper or a vibratome is used to cut the brain into 300–400 μm slices. The hippocampus is dissected carefully from slices for culturing. Two methods have been developed to maintain thin slices: the roller tube and the membrane interface method [13,18–20]. The conventional roller tube technique is associated with preparation difficulties and large experimental variabilities [1]. Thus, membrane interface culture has become the most frequently used method [1]. In this method, brain slices are maintained on a porous membrane insert while the medium below the membrane provides nutrients to tissues by capillary action [1,13]. The standard culture medium consists of 50% MEM, 25% heat-inactivated horse serum, and 25% HBSS, supplemented with final concentrations of 25 mM glucose, 2 mM glutamine, or 12.5 mM HEPES and penicillin–streptomycin [17,21–23]. The slices are incubated at 34–37°C in a humidified atmosphere of 5% CO_2 [23–25]. Mechanical lesions and alterations in metabolic state caused by release of enzymes and iron during tissue slicing are repaired during the first 6–18 days of culture [13]. After several weeks, the slices eventually thin down to 5–8 layers of cells (~100 μm) [13]. For use in experiments that mimic ischemia or excitotoxicity, a low-serum or serum-free medium may be used, or conditioned medium can be applied based on the experimental targets [26].

Healthy, undamaged slices are crucial for successful experiments and for minimizing experimental variation. On a healthy hippocampal slice, one should be able to easily identify cell bodies of pyramidal cells in CA1 and CA3 regions under a 40 $\times$ objective and smooth cell somata on the slice surface [13]. Various stains can also be used to help identify healthy slices. For example, propidium iodide (PI) is used to stain dead cells, and immunostains for markers of neurons and synapses can be used to identify lesions, certain healthy cell populations, and tissue architecture.

Experimental applications of OHSC in stroke and TBI

The technique of oxygen-glucose deprivation (OGD) mimics the conditions of ischemic stroke *in vitro*. A variety of neuroprotective mechanisms have been studied with the OGD model [25,27,28]. The hippocampal CA1 area is highly susceptible to OGD timing in OHSCs [29–31]. Variations in the time of pre-incubation, temperature, and co-cultured cells strongly affect cell death [32–35].

PI is widely used to detect disrupted cells in slice culture. It binds to DNA in a nonspecific manner by penetrating the damaged phospholipid bilayers. Although PI cannot distinguish apoptotic and necrotic processes, it is accepted to correlate well with the overall number of damaged cells [36,37]. PI staining fails to distinguish the damaged cell population, but provides an idea of the major damaged cell type by the unique structure of hippocampus. The concentration of PI usually used is 5 µg/ml, and 30 minutes to 1 hour is an effective incubation period. Alternatively, damaged cells can be stained with Sytox Green (5 µM) for 30 minutes [38]. Cell death is calculated as $100 \times (P_x - P_0) / (P_{\max} - P_0)$, where P_x is the fluorescence intensity of slices at a certain time point, P_0 is the background (baseline) fluorescence, and $P_{\max}$ is the maximum fluorescence intensity of slices after a toxic dose of N-methyl-D-aspartate (NMDA), glutamate, or hypothermia, etc. [36,39,40].

Immunohistology is performed directly on the slices after different experimental treatments. Some groups prefer to perform the cryosection on OHSCs (20 µm) before immunodetection [41]. Ultrastructure, such as mitochondria, endoplasmic reticulum, and dendrites, can be observed by electron microscopy after traumatic insult [42].

Biochemical characteristics

No special treatment is required to extract protein and mRNA from cultured slices except for pooling of samples. Five to six slices of rat hippocampus should be pooled [43,41]. More slices are needed to extract proteins from mouse OHSCs.

An enzyme-linked immunosorbent assay (ELISA) kit is usually used to measure secreted proteins such as cytokines and chemokines in the culture medium of OHSCs. The overexpression of tumor necrosis factor α (TNF α), interleukin-6 (IL-6), and interleukin-1 β (IL-1 β) has been detected as early as 60 minutes after 60-minute OGD [44].

mRNA microarrays can be performed and analyzed from slices subjected to hypoxia and OGD models [45]. Hypoxic preconditioning has been shown to upregulate apoptosis/survival-related genes, and isoflurane exposure has been shown to upregulate cell cycle/development genes such as Egr and Pten [45]. Proteins that regulate apoptosis, such as B-cell lymphoma 2 (Bcl-2), P53, and murine double minute (MDM2), can be analyzed by Western blotting for evaluation of cell death pathways [46,45].

Electrophysiologic function

Organotypic slice culture permits long-term exposure to chemicals or drugs. Moreover, the chronic exposure may produce results that are opposite of those obtained in acute experiments [47]. After TBI is induced in hippocampal slice culture, the response amplitude,

threshold intensity to obtain 50% maximal response, and spontaneous oscillations are recorded [48,49]. Stretchable microelectrode arrays (SMEAs) have been developed to record neuronal activity from multiple electrodes. Unlike typical electrodes, SMEAs deform with the tissue during TBI-induced stretching [49]. SMEAs can stimulate and detect electrical activity from cultured tissue without causing additional mechanical damage [50].

Neural genesis (axogenesis, gliogenesis)

To determine the fate of newly generated neurons and glial cells, Strassburger *et al* [41]. detected proliferating cells by using BrdU (5-bromo-2-deoxyuridine), and by labeling with specific cell markers sequentially. At 1 week after 40-minute OGD, little endogenous neurogenesis had occurred, as detected by doublecortin, the early neuronal marker; on the contrary, the majority of BrdU-positive cells were microglia or GFAP-positive cells [51]. When the injured OHSCs were treated with anti-inflammatory agents, neurogenesis was induced in the posterior periventricular zone at 6 days after 40-minute OGD [41]. Sierra *et al.* [52] also showed that microglia in the hippocampus can regulate neurogenesis through phagocytosis. Moreover, neural progenitor cells can be grafted to the slice cultures to study chemokines that regulate their migration and to investigate survival [53], differentiation, synaptogenesis, and function of the transplanted cells [54–56,35]. In comparison with neurogenesis, endothelial cell remodeling and angiogenesis have not been studied in OHSC [57,58].

Hypothermia

Mild hypothermia after OGD produces regional and time-dependent neuroprotective effects [59]. Gregersen *et al.* [60] cooled the slices with mild (33°C–34°C), moderate (<25°C), and profound hypothermia (<20°C) to investigate the limitations of hypothermia after 60-minute OGD. They found that the protective effect of mild and moderate hypothermia was time-dependent and that profound hypothermia increased cell death.

Co-culture and transgenic mice

To study the role of microglia in neuroprotection and neurodegeneration, microglia can be depleted from OHSCs with chemicals such as saporin. The depletion of microglia was shown to increase neurodegeneration at 1, 7, and 14 days after 30-minute OGD [61]. Conversely, microglia can be added to the slice cultures. Microglia provided a neuroprotective effect when applied up to 4 hours after 40-minute OGD [62]. Protein-dependent function can be studied by using shRNA to knock down a gene in OHSC or by culturing slices from knockout or transgenic animals [63,64,53,65].

Applications to stroke

In 2000 and 2012, stroke was the second leading cause of death in the world (<http://www.who.int/mediacentre/factsheets/fs310/en/>). Even with timely treatment, it still may cause severe long-term sequelae, including unilateral paralysis, awareness and memory problems, speech problems, limb pain, and even depression owing to onset and delayed neuronal cell death and secondary neuroinflammation. The pathogenic mechanisms,

neuroprotection, and repair mechanisms of stroke need to be investigated, and potentially effective drugs need to be tested in preclinical or translational research.

Ischemic stroke

Ischemic stroke accounts for approximately 87% of all strokes and is the most well-studied stroke type. Because OGD can mimic the conditions of ischemic stroke in hippocampal slice cultures, which represent a complex mixed-cell population, it has been commonly used in ischemic stroke studies since 1996 [66,67]. Pathogenic mechanisms of acute and delayed neuronal loss that have been studied in OHCS include cellular energy depletion, accumulation of extracellular glutamate and other excitotoxins, calcium overload, mitochondrial dysfunction, and oxidative stress [66]. CA1 pyramidal cells are most vulnerable to OGD; the CA3 and dentate gyrus regions are less vulnerable [66,68]. OGD has been shown to induce apoptosis [69,70], necrosis [71], and a mixture of both [72]. The differences in cell death type might depend heavily on the duration of OGD (short OGD tends to cause apoptosis, whereas longer OGD causes necrosis) and the oxygen concentration [73]. Studies in which different kinds of cell death are targeted have been carried out for years. Pretreatment with caspase inhibitor Ac-YVAD-cmk (1 hour before until 24 hours after OGD) protected against CA1 cell death and also prevented synaptic dysfunction [68]. Another caspase inhibitor, z-VAD-fmk, also provided a neuroprotective effect when administered during and after 30-minute OGD [74]. However, inhibitors of poly (ADP-ribose) polymerase have no neuroprotective effect and have even caused more cell death when tested in OHSCs [74,70,73]. Although many groups have tried, it is not easy to replicate the typical time pattern of neuronal cell death after global ischemia with OGD *in vitro* or *ex vivo*: acute cell death in the dentate hilus followed by delayed cell death in the CA1. For now, OGD is a common *ex vivo* model used to study the molecular and cellular mechanisms of ischemic stroke and the effectiveness of neuroprotective compounds in OHSCs.

Application of glutamate is believed to mimic excitotoxicity that occurs as a consequence of ischemic stroke. Excess glutamate, which is released into the extracellular space by damaged cells, can overexcite ionotropic and G-coupled metabotropic glutamate receptors and thereby accelerate calcium ion entry into the cell. Calcium can also cause the release of more glutamate. Glutamate can bind to two types of receptors: ionotropic receptors [including NMDA, kainate, and AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazole propionate)] and metabotropic glutamate receptors. Metabotropic glutamate receptors can be excited by L-AP4 (L-2-amino-4-phosphonobutyric acid), ACPD (1-amino-1,3-dicarboxycyclopentane), and L-QA (L-quisqualic acid) [75,66]. Exposing OHSCs to NMDA and AMPA causes CA1 pyramidal cell death [76,77]. Neurons located in CA3 are particularly responsive to administration of kainic acid (KA) and domoic acid [76–81]. Interestingly, different agonists induce different types of cell death. For example, KA caused necrosis but not apoptosis in OHSCs [80]. Antagonists of glutamate receptors have been tested in conjunction with OGD. Repeated studies have shown that treating OHSCs with MK-801, an NMDA antagonist, rescues most neurons from death during and after OGD [82–86,7], but results regarding whether post-treatment with MK-801 protects against neuronal death have been conflicting [86,7]. CNQX (6-Cyano-7-nitroquinoxaline-2,3-dione) protected against damage from

glutamate, and GYKI 52466 and NBQX (2,3-dihydro-6-nitro-7-sulfamoyl-benzo-quinoline) showed protection against KA, AMPA, and ATPA [(RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propionic acid] toxicity [77,87].

Calcium influx into the damaged neurons is a cause of cell death after stroke. Ion channels and activated NMDA, AMPA, and KA receptors are highly permeable to calcium [88–93]. Sodium Influx through NMDA, AMPA, and KA receptors also causes calcium overload that is mediated by voltage-sensitive calcium channels [66]. Therefore, the efficacy of calcium channel blockers and tetrodotoxin, a sodium channel blocker, has been tested by PI staining and electrophysiology methods [67,94,83]. Importantly, both L-type and N-type calcium channel blockers have been shown to provide neuroprotection *in vivo* and *in vitro*, but it was not clear whether the protection was through the vasculature or neurons [67]. OHSCs provided a unique platform that enabled researchers to determine that the effect of an N-type calcium channel antagonist (omega conotoxin MVIIA) was mediated directly through neuronal calcium channels, whereas the effect of dihydropyridines (which block L-type calcium channels) might be mediated through vascular calcium channels or indirectly through actions in other brain regions [67].

Calcium influx leads to activation of the mitochondrial permeability transition pore (MPTP). The resulting depolarization of the mitochondria causes a loss of ATP production, an increase in reactive oxygen species (ROS), and damage to cytochromes in the electron transport chain [66,95–98]. The increased presence of ROS and calcium within the mitochondria leads to lipid peroxidation and membrane damage [66]. Nitric oxide (NO) accumulates and reacts with superoxide anion to form peroxynitrite, which causes additional cell damage and leads to apoptotic and necrotic cell death [66,97]. Mitochondrial inhibitors (3-nitropropionic acid), compounds that induce glutathione depletion (l-buthionine-sulfoximine), and other reagents have been used to mimic the pathological process of ROS generation in OHSCs [66]. Neuroprotective compounds like RU486, an antagonist of progesterone and glucocorticoid receptors, have been shown to protect against the effects of ROS-induced cell death, including amyloid beta protein, hydrogen peroxide, and glutamate overloading [99]. This protective effect was independent of the presence or activation of glucocorticoid or progesterone receptors [99]. Genipin, the multipotent ingredient in gardenia jasmenoides fruit extract, was also able to reduce cell death stemming from ROS and reactive nitrogen species production [38]. In addition, mild hypothermia (31–33°C) has been shown to protect against OGD-induced (60 min) neuronal death by reducing free radical production [100].

Damaged neurons undergo cellular degeneration after the onset of cerebral ischemic stroke. During this process, the injured neurons upregulate stress-related signaling pathways and secrete chemokines/cytokines that strongly activate nearby glial cells [101–103]. In response to the inflammatory signals, microglia/macrophages are recruited to the infarct area, where they contribute to phagocytosis of damaged neurons, formation of scar tissue, and secondary inflammation. The secondary inflammation potentially increases cerebral infarct size and worsens clinical outcome of patients with ischemic stroke [103–105]. It is commonly accepted that microglia/macrophages have two distinct activation phenotypes. The M1, or classically activated phenotype, is associated with secretion of inflammatory cytokines and

generation of ROS, whereas the M2, or alternatively activated phenotype, is believed to secrete anti-inflammatory factors, phagocytize damaged neurons, and contribute to regeneration of injured tissues [106]. The ability to manipulate microglial/macrophage activation after stroke could affect ischemic stroke outcomes. D-JNKI1, a specific JNK inhibitor, was shown to decrease activation of microglia after 30-minute OGD through the JNK pathway in neurons [103]. Additionally, the expression and activity of matrix metalloproteinase (MMP) 9 was increased after OGD (48 hours) in microglia; treatment with either MMP inhibitor AG3340 (prinomastat) or minocycline reduced OGD-induced (48 hours) gelatinolytic activity as well as neural injury [107]. Moreover, histone deacetylase inhibitors trichostatin A and suberoylanilide hydroxamic acid inhibited lipopolysaccharide-induced microglial activation by decreasing the secretion of IL-6, macrophage inflammatory protein-2, and NO. This effect may be mediated by the NF- κ B pathway [108].

Hemorrhagic stroke

Fewer studies have used OHSCs to model hemorrhagic stroke. Nicaraven is an agent that is especially beneficial in vasospasm or brain damage caused by subarachnoid hemorrhage (SAH) [109]. In the only study that used OHSCs to model SAH, nicaraven was reported to protect neurons from 30-minute OGD and/or NMDA-induced cell death by inhibiting poly (ADP-ribose) synthase and scavenging free radicals [109]. To our knowledge, no published study has used OHSCs to investigate the pathophysiology of intracerebral hemorrhage. Hemoglobin, a main component of blood, has been reported to bind with NO and block long-term potentiation of CA1 neurons [110]. Other blood components that may have an impact on neuronal toxicity, such as thrombin, have been studied with OHSCs. However, such studies are usually considered to benefit ischemia, but not hemorrhage [111]. Thrombin has been reported to protect neurons from OGD at low concentrations (50 pM, 0.01 unit/ml), but it reduced neuronal survival at higher concentrations (50 nM, 10 units/ml) [111]. The molecular mechanism by which thrombin causes injury may relate to FXa (perinuclear activated factor X), which catalyzes the conversion of prothrombin to thrombin in neural tissue after ischemia [112]. Protease nexin-1 and L-JNKI1 were able to prevent the neuronal injury caused by thrombin [113,114].

Application to TBI

TBI is one of the most common neurologic disorders and is generally graded into mild, moderate, and severe. Based on a Centers for Disease Control and Prevention (CDC) report, an estimated 1.7 million people sustain acute TBI in the U.S. annually, and approximately 53,000 people die of TBI-related injury [115]. TBI consists of the primary injury, which occurs at the moment of impact, and secondary injury, which is characterized by brain swelling, hypoxia, hypotension, and a complex cascade of neuroinflammatory and metabolic events that lead to death or neurologic damage over time [116]. Although specific therapy for TBI is lacking, understanding the pathogenesis of TBI-induced brain injury is necessary. Here, we summarize studies that have used OHSCs to investigate TBI and the techniques and analytical tools that were used.

Induction of TBI in slice cultures

TBI can be mimicked in organotypic slice cultures by several methods. In one, a stainless steel cylinder (0.9 g) is rolled on the slices to mimic the primary traumatic injury of head-impact accidents [36]. In another model, a metal stylus or weight (0.137 g) is held 2 mm or 7 mm above the slice and then allowed to fall onto a localized area [36,117]. This model induces secondary injury, enabling the researcher to follow the spread of cell injury, hypoxic damage, and brain swelling [118]. The third method is stretch injury, known to generate an equibiaxial strain injury [117,119]. The frequency and speed of the strain are controlled by a linear actuator, linear encoder, and motion control board. The device allows up to 100% control of tissue strain and strain rate (up to 150 s^{-1}) [120]. Cell damage after injury closely correlates with strain [121]. Of note, although 5% and 10% biaxial lagrangian strain induced minimal cell death, as determined by PI staining [122,123], the maximal evoked response and the excitability of neural networks were decreased [48].

Cell death (PI staining)

PI uptake is used to indicate cell damage. When a mechanical TBI model was used, PI was increased significantly at 72 hours. Application of dexmedetomidine by 2 hours provided optimal protection, and MEK1-ERK was considered to be involved in mediating dexmedetomidine's protective effect [124].

Metabolism and gene expression

Most TBIs are mild [125]. Di Pietro *et al.* [117] compared the mRNA levels of various genes after a 10% (mild) and 50% (severe) stretch in slice cultures. They found that more genes were differentially expressed after mild TBI than after severe stretch, 210 vs. 161 for upregulated genes and 789 vs. 426 for downregulated genes. These genes were involved in a variety of cellular processes, such as multicellular organismal development, nucleosome organization, and chromatin assembly. Interestingly, severe stretch injury also activated neurodegenerative pathways such as the RhoA (Ras homolog gene family, member A) signaling pathway. The same investigators also investigated the metabolism of mild TBI [119]. HPLC results showed that ATP, ATP/ADP, and mitochondrial function were decreased, and gene microarray data indicated downregulation of transcriptional and translational genes at 24 hours after mild TBI. These data indicate that a hibernation-type response was activated after mild TBI [119].

Activation of microglia

After TBI, quiescent microglial cells with ramified processes become activated and take on an amoeboid morphology. *In vivo*, monocytes, neutrophils, and lymphocytes accumulate at the site of the lesion as a result of a breached blood-brain barrier [126–128]. These inflammatory cells release cytokines that contribute to secondary brain damage. Inflammatory cells also activate the complement cascade, which increases vascular permeability and secondary neuronal insults in both rodent and human brain [129,130]. Activated microglia and blood-sourced macrophages are very hard to differentiate morphologically or by surface markers *in vivo*. Therefore, Bellander *et al.* [131] used OHSCs to evaluate the contribution of activated microglia to complement production after

TBI. Their findings support the premise that microglia play a key role in complement activation after TBI, even in the absence of blood cells.

ROS

After TBI, secondary injury induces an extended cascade of pathological sequelae, including damage by ROS, reactive nitrogen species, and lipid peroxidation. Each contributes to damage of protein, DNA/RNA, cell membrane phospholipid architecture, and integrity of the blood-brain barrier [132,133]. Various antioxidant agents have been shown to be protective in TBI models, including U-83836E, a potent and selective scavenger of LOO (*) radicals [134]; phenelzine, a scavenger of lipid peroxidation [135]; and deferoxamine, which inhibits iron toxicity [136]. Most of these investigations were performed *in vivo*. Recently, one *ex vivo* study on cultured rat hippocampal slices by Hughes *et al.* [38] showed that genipin protected against oxidative stress induced by *tert*-butyl hydroperoxide when it was administered at 1, 6, or 24 hours after injury. No protection was detected when treatment was delayed by 36 hours. ROS injury occurs soon after TBI. Huang and Huang [137] summarized 143 published *in vivo* and *in vitro* TBI studies and found that in most, ROS was sampled at 30 minutes to 1 hour after acute TBI. However, *ex vivo* brain slice culture might provide a good model to investigate ROS as early as several minutes after TBI.

Epilepsy after TBI

TBI causes epilepsy and chronic seizures that are triggered by hyperexcitable networks [138,139]. Extracellular electrophysiological recordings revealed that cortical oscillatory activity after TBI was suppressed [140]. Only 28% of slices showed evoked activity 48 hours after TBI, and the network activity recovered to baseline at 15 days after TBI [140]. The level of cyclooxygenase-2 and prostaglandin E2 (PGE2) increased after TBI [47]. In contrast to acute, postsynaptic application of PGE2, which decreases excitatory synaptic transmission in cultured slices, long-term (48 hours) exposure to PGE2 upregulated presynaptic excitatory synaptic transmission, which may evoke a cascade of events that leads to epileptogenesis [47].

In early studies of TBI in OHSCs, researchers investigated fiber sprouting and functional regeneration. GAP-43 (growth-associated protein-43), a marker of axonal growth, was expressed by newly sprouted axons after transection of the CA3-CA1 transition [141]. Elevated local connection by increased presynaptic boutons caused hyperexcitability, which contributed to the genesis of seizures. TBI induced secretions of neurotrophic factors such as epidermal growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor [142,143]. These factors might promote axonal connections by improving sprouting [144,145]. Experiments in slice cultures have recently shown that interfering with the actions of these factors to reduce axonal sprouting might reduce the risk of hyperexcitability and epilepsy development [146].

Conclusion, limitations, and prospects

Chronic hippocampal slice culture has become a valuable platform to study both normal and diseased brain functions. Because OHSC preserves the entire structure of hippocampus as it

relates to neurogenesis, synaptogenesis, and axogenesis, it can be used as an *ex vivo* model of stroke and TBI to investigate not only acute neuronal cell death, but also neurogenesis and neuroplasticity [1]. As discussed in this review, OHSC has a number of advantages as an *ex vivo* system. It is a fast, simple, and precisely controlled system; it preserves the three-dimensional neuronal network and therefore is closer to an animal model than is cell culture; it reduces the number of animals needed; slices can be co-cultured with slices from different brain tissue or with specific cell populations to assess the interactions between them; and the effects of compounds and drugs can be investigated without concern about their ability to pass through the blood-brain barrier [1,147].

Compared to the tri-culture system that artificially assembles various cell types (endothelial cells, pericytes, and astrocytes or endothelial cells, neurons, and astrocytes) *in vitro*, OHSC contains all cell types and can be used to study cell-cell interactions under a variety of pathologic conditions. However, as an *ex vivo* model, the OHSC system shares many disadvantages with *in vitro* systems. For example it lacks the influence of factors such as blood perfusion, cerebrovascular autoregulation, intracranial pressure, and neurovascular coupling, etc., which are involved in pathophysiology of both stroke and TBI. Moreover, OHSC may have limitations for the study of calcium ions after stroke or TBI given the multiple homeostatic processes (Na^+ - Ca^{2+} exchange, mitochondrial and endoplasmic reticular calcium accumulation, protein binding, etc.) involved in the maintenance of intracellular calcium, especially when compounded by mitochondrial abnormalities. Importantly, OHSC is only suitable for examining the short-term effect of drugs on various injuries because the slices cannot survive for more than 3 weeks *in vitro* and will die within 3 days after intense or prolonged injury. It is also important to remember that the results obtained from OHSCs are only an approximation of what occurs in hippocampus of the mature animal brain. Studies have shown that neurons in OHSCs have more branches, higher order of dendrites, and more complicated synapses than those in acute slices [11]. Our group also observed that the morphology of astrocytes and microglia in OHSCs differs from that in frozen brain sections. Considering the cell reprogramming that could occur in an artificial environment with environmental pressures that differ from those *in vivo*, potential epigenetic changes in protein expression should make researchers evaluate their results more carefully. Although acute OHSCs may be more representative of mature brain than chronic OHSCs, acute slices have been used mostly for electrophysiology studies [148], rather than the examination of pathologic aspects described in this review. Only a few studies have reported using acute slice systems for stroke and TBI research [149–151]. Moreover, acute slices might have their own limitations. A recent study [152] indicated that astrocytes in acute slices exhibit structural and functional differences from those *in vivo*, including upregulated expression of GFAP, nestin, connexin 43, and AQP4; increased interstitial space volume; and different Ca^{2+} responses. Thus, acute and chronic OHSCs have their own advantages and disadvantages with regard to simulating *in vivo* conditions. Of course, *in vivo* animal models are still ultimately necessary to evaluate the anatomic and functional outcomes of a therapeutic strategy.

Although most molecular biology techniques can be used in OHSCs with minor modifications, technical difficulties need to be resolved, such as how to quantify the morphology scientifically with 5–7 layers of cells, how to extract proteins with fewer slices,

and how to decrease the variation in PI staining. Additionally, it is not yet clear whether gender and age of the pups, percentage of serum in the medium, and *in vitro* culture time affect certain experimental results.

To date, a limited number of studies have used OHSCs to study TBI, and even fewer publications focus on hemorrhagic stroke. Given its advantages, it might be beneficial to use this valuable platform more often for TBI and hemorrhagic stroke research.

Acknowledgements

This work was supported by an AHA Mid-Atlantic Affiliate Grant-in-Aid 13GRNT15730001, NIH grants R01NS078026 and R01AT007317 (JW), and an AHA Mid-Atlantic Affiliate Postdoctoral Fellowship Award (XH).

References

1. Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. *Curr Neuroparmacol*. 2007; 5(1):19–33. [PubMed: 18615151]
2. Gogolla N, Galimberti I, DePaola V, Caroni P. Staining protocol for organotypic hippocampal slice cultures. *Nat Protoc*. 2006; 1(5):2452–2456. doi:10.1038/nprot.2006.180. [PubMed: 17406491]
3. Birgbauer E, Rao TS, Webb M. Lysolecithin induces demyelination *in vitro* in a cerebellar slice culture system. *J Neurosci Res*. 2004; 78(2):157–166. doi:10.1002/jnr.20248. [PubMed: 15378614]
4. Krassioukov AV, Ackery A, Schwartz G, Adamchik Y, Liu Y, Fehlings MG. An *in vitro* model of neurotrauma in organotypic spinal cord cultures from adult mice. *Brain Res Brain Res Protoc*. 2002; 10(2):60–68. [PubMed: 12431704]
5. Newell DW, Barth A, Papermaster V, Malouf AT. Glutamate and non-glutamate receptor mediated toxicity caused by oxygen and glucose deprivation in organotypic hippocampal cultures. *J Neurosci*. 1995; 15(11):7702–7711. [PubMed: 7472521]
6. Phillis JW, Smith-Barbour M, Perkins LM, O'Regan MH. Characterization of glutamate, aspartate, and GABA release from ischemic rat cerebral cortex. *Brain Res Bull*. 1994; 34(5):457–466. [PubMed: 7915962]
7. Rytter A, Cronberg T, Asztely F, Nemali S, Wieloch T. Mouse hippocampal organotypic tissue cultures exposed to *in vitro* “ischemia” show selective and delayed CA1 damage that is aggravated by glucose. *J Cereb Blood Flow Metab*. 2003; 23(1):23–33. [PubMed: 12500088]
8. Molnar Z, Blakemore C. Development of signals influencing the growth and termination of thalamocortical axons in organotypic culture. *Exp Neurol*. 1999; 156(2):363–393. doi:10.1006/exnr.1999.7032. [PubMed: 10328943]
9. Gong Q, Liu WL, Srodon M, Foster TD, Shipley MT. Olfactory epithelial organotypic slice cultures: a useful tool for investigating olfactory neural development. *Int J Dev Neurosci*. 1996; 14(7–8):841–852. [PubMed: 9010729]
10. Bahr BA. Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. *J Neurosci Res*. 1995; 42(3):294–305. doi:10.1002/jnr.490420303. [PubMed: 8583497]
11. De Simoni A, Griesinger CB, Edwards FA. Development of rat CA1 neurones in acute versus organotypic slices: role of experience in synaptic morphology and activity. *J Physiol*. 2003; 550(Pt 1):135–147. doi:10.1113/jphysiol.2003.039099. [PubMed: 12879864]
12. Rivera S, Gold SJ, Gall CM. Interleukin-1 beta increases basic fibroblast growth factor mRNA expression in adult rat brain and organotypic hippocampal cultures. *Brain Res Mol Brain Res*. 1994; 27(1):12–26. [PubMed: 7533232]
13. De Simoni A, Yu LM. Preparation of organotypic hippocampal slice cultures: interface method. *Nat Protoc*. 2006; 1(3):1439–1445. doi:10.1038/nprot.2006.228. [PubMed: 17406432]
14. Cooke SF, Bliss TV. Long-term potentiation and cognitive drug discovery. *Curr Opin Investig Drugs*. 2005; 6(1):25–34.

15. Finley M, Fairman D, Liu D, Li P, Wood A, Cho SG. Functional validation of adult hippocampal organotypic cultures as an in vitro model of brain injury. *Brain Research*. 2004; 1001(1–2):125–132. doi:DOI 10.1016/j.brainres.2003.12.009. [PubMed: 14972661]
16. Xiang Z, Hrabetova S, Moskowitz SI, Casaccia-Bonnel P, Young SR, Nimmrich VC, Tiedge H, Einheber S, Karnup S, Bianchi R, Bergold PJ. Long-term maintenance of mature hippocampal slices in vitro. *J Neurosci Methods*. 2000; 98(2):145–154. [PubMed: 10880828]
17. Bai JZ, Lipski J. Involvement of TRPV4 channels in Abeta(40)-induced hippocampal cell death and astrocytic Ca(2+) signalling. *Neurotoxicology*. 2014; 41:64–72. doi:10.1016/j.neuro.2014.01.001. [PubMed: 24457011]
18. Gahwiler BH. Organotypic monolayer cultures of nervous tissue. *J Neurosci Methods*. 1981; 4(4):329–342. [PubMed: 7033675]
19. Hogue MJ. Human fetal brain cells in tissue cultures; their identification and motility. *J Exp Zool*. 1947; 106(1):85–107. [PubMed: 20268087]
20. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. *J Neurosci Methods*. 1991; 37(2):173–182. [PubMed: 1715499]
21. Gerace E, Landucci E, Scartabelli T, Moroni F, Pellegrini-Giampietro DE. Rat hippocampal slice culture models for the evaluation of neuroprotective agents. *Methods Mol Biol*. 2012; 846:343–354. doi:10.1007/978-1-61779-536-7_29. [PubMed: 22367824]
22. Hellwig S, Hack I, Kowalski J, Brunne B, Jarowij J, Unger A, Bock HH, Junghans D, Frotscher M. Role for Reelin in neurotransmitter release. *J Neurosci*. 2011; 31(7):2352–2360. doi:10.1523/JNEUROSCI.3984-10.2011. [PubMed: 21325502]
23. Yoon JJ, Green CR, O'Carroll SJ, Nicholson LF. Dose-dependent protective effect of connexin43 mimetic peptide against neurodegeneration in an ex vivo model of epileptiform lesion. *Epilepsy Res*. 2010; 92(2–3):153–162. doi:10.1016/j.eplepsyres.2010.08.014. [PubMed: 20851574]
24. Kim HA, Lee KH, Lee BH. Neuroprotective effect of melatonin against kainic acid-induced oxidative injury in hippocampal slice culture of rats. *Int J Mol Sci*. 2014; 15(4):5940–5951. doi:10.3390/ijms15045940. [PubMed: 24722567]
25. Lamprecht MR, Morrison B 3rd. GPR30 activation is neither necessary nor sufficient for acute neuroprotection by 17beta-estradiol after an ischemic injury in organotypic hippocampal slice cultures. *Brain Res*. 2014; 1563:131–137. doi:10.1016/j.brainres.2014.03.037. [PubMed: 24704272]
26. Horn AP, Bernardi A, Luiz Frozza R, Grudzinski PB, Hoppe JB, de Souza LF, Chagastelles P, de Souza Wyse AT, Bernard EA, Battastini AM, Campos MM, Lenz G, Nardi NB, Salbego C. Mesenchymal stem cell-conditioned medium triggers neuroinflammation and reactive species generation in organotypic cultures of rat hippocampus. *Stem Cells Dev*. 2011; 20(7):1171–1181. doi:10.1089/scd.2010.0157. [PubMed: 20955077]
27. Van Kanegan MJ, He DN, Dunn DE, Yang P, Newman RA, West AE, Lo DC. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin. *J Neurosci*. 2014; 34(3):963–968. doi:10.1523/JNEUROSCI.2700-13.2014. [PubMed: 24431454]
28. Chip S, Nitsch C, Wellmann S, Kapfhammer JP. Subfield-specific neurovascular remodeling in the entorhino-hippocampal-organotypic slice culture as a response to oxygen-glucose deprivation and excitotoxic cell death. *J Cereb Blood Flow Metab*. 2013; 33(4):508–518. doi:10.1038/jcbfm.2012.190. [PubMed: 23232944]
29. Petito CK, Feldmann E, Pulsinelli WA, Plum F. Delayed hippocampal damage in humans following cardiorespiratory arrest. *Neurology*. 1987; 37(8):1281–1286. [PubMed: 3614648]
30. Nitsch C, Goping G, Klatzo I. Preservation of GABAergic perikarya and boutons after transient ischemia in the gerbil hippocampal CA1 field. *Brain Res*. 1989; 495(2):243–252. [PubMed: 2765929]
31. Kirino T, Tamura A, Sano K. Delayed neuronal death in the rat hippocampus following transient forebrain ischemia. *Acta Neuropathol*. 1984; 64(2):139–147. [PubMed: 6475501]
32. Hassen GW, Tian D, Ding D, Bergold PJ. A new model of ischemic preconditioning using young adult hippocampal slice cultures. *Brain Res Brain Res Protoc*. 2004; 13(3):135–143. doi:10.1016/j.brainresprot.2004.03.004. [PubMed: 15296850]

33. Feiner JR, Bickler PE, Estrada S, Donohoe PH, Fahlman CS, Schuyler JA. Mild hypothermia, but not propofol, is neuroprotective in organotypic hippocampal cultures. *Anesth Analg.* 2005; 100(1): 215–225. doi:10.1213/01.ANE.0000142129.17005.73. [PubMed: 15616081]
34. Ko H, Zeller M, Gabriel S, Graulich J, Heinemann U, Obladen M. Mild postischemic hypothermia is neuroprotective in the immature rat neocortex slice. *Brain Res.* 2001; 894(2):297–300. [PubMed: 11251204]
35. Sarnowska A, Braun H, Sauerzweig S, Reymann KG. The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. *Exp Neurol.* 2009; 215(2):317–327. doi:10.1016/j.expneurol.2008.10.023. [PubMed: 19063882]
36. Adamchik Y, Frantseva MV, Weissapir M, Carlen PL, Perez Velazquez JL. Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. *Brain Res Brain Res Protoc.* 2000; 5(2):153–158. [PubMed: 10775835]
37. Tasker RC, Coyle JT, Vornov JJ. The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. *J Neurosci.* 1992; 12(11):4298–4308. [PubMed: 1359034]
38. Hughes RH, Silva VA, Ahmed I, Shreiber DI, Morrison B 3rd. Neuroprotection by genipin against reactive oxygen and reactive nitrogen species-mediated injury in organotypic hippocampal slice cultures. *Brain Res.* 2014; 1543:308–314. doi:10.1016/j.brainres.2013.11.020. [PubMed: 24275198]
39. Ikeda-Matsuo Y, Tanji H, Ota A, Hirayama Y, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors. *Br J Pharmacol.* 2010; 160(4):847–859. [PubMed: 20590584]
40. Fujimoto S, Katsuki H, Kume T, Akaike A. Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures. *Neurobiol Dis.* 2006; 22(1):130–142. doi:S0969-9961(05)00279-2 [pii] 1016/j.nbd.2005.10.008. [PubMed: 16330215]
41. Strassburger M, Braun H, Reymann KG. Anti-inflammatory treatment with the p38 mitogen-activated protein kinase inhibitor SB239063 is neuroprotective, decreases the number of activated microglia and facilitates neurogenesis in oxygen-glucose-deprived hippocampal slice cultures. *Eur J Pharmacol.* 2008; 592(1–3):55–61. doi:10.1016/j.ejphar.2008.06.099. [PubMed: 18638472]
42. Jung YJ, Suh EC, Lee KE. Oxygen/Glucose Deprivation and Reperfusion Cause Modifications of Postsynaptic Morphology and Activity in the CA3 Area of Organotypic Hippocampal Slice Cultures. *Korean J Physiol Pharmacol.* 2012; 16(6):423–429. doi:10.4196/kjpp.2012.16.6.423. [PubMed: 23269905]
43. Ahlgren H, Henjum K, Ottersen OP, Runden-Pran E. Validation of organotypical hippocampal slice cultures as an ex vivo model of brain ischemia: different roles of NMDA receptors in cell death signalling after exposure to NMDA or oxygen and glucose deprivation. *Cell Tissue Res.* 2011; 345(3):329–341. doi:10.1007/s00441-011-1218-2. [PubMed: 21874291]
44. Bernardi A, Frozza RL, Horn AP, Campos MM, Calixto JB, Salbego C, Pohlmann AR, Guterres SS, Battastini AM. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. *Neurochem Int.* 2010; 57(6):629–636. doi:10.1016/j.neuint.2010.07.012. [PubMed: 20691236]
45. Bickler PE, Fahlman CS. Expression of signal transduction genes differs after hypoxic or isoflurane preconditioning of rat hippocampal slice cultures. *Anesthesiology.* 2009; 111(2):258–266. doi:10.1097/ALN.0b013e3181a8647f. [PubMed: 19568165]
46. Cui HS, Matsumoto K, Murakami Y, Hori H, Zhao Q, Obi R. Berberine exerts neuroprotective actions against in vitro ischemia-induced neuronal cell damage in organotypic hippocampal slice cultures: involvement of B-cell lymphoma 2 phosphorylation suppression. *Biol Pharm Bull.* 2009; 32(1):79–85. [PubMed: 19122285]
47. Koch H, Huh SE, Elsen FP, Carroll MS, Hodge RD, Bedogni F, Turner MS, Hevner RF, Ramirez JM. Prostaglandin E2-induced synaptic plasticity in neocortical networks of organotypic slice cultures. *J Neurosci.* 2010; 30(35):11678–11687. doi:10.1523/JNEUROSCI.4665-09.2010. [PubMed: 20810888]

48. Yu Z, Elkin BS, Morrison B. Quantification of functional alterations after in vitro traumatic brain injury. *Conf Proc IEEE Eng Med Biol Soc.* 2009; 2009:1135–1138. doi:10.1109/IEMBS.2009.5332381. [PubMed: 19963487]
49. Yu Z, Graudejus O, Lacour SP, Wagner S, Morrison B 3rd. Neural sensing of electrical activity with stretchable microelectrode arrays. *Conf Proc IEEE Eng Med Biol Soc.* 2009; 2009:4210–4213. doi:10.1109/IEMBS.2009.5333791. [PubMed: 19964344]
50. Yu Z, Graudejus O, Tsay C, Lacour SP, Wagner S, Morrison B 3rd. Monitoring hippocampus electrical activity in vitro on an elastically deformable microelectrode array. *J Neurotrauma.* 2009; 26(7):1135–1145. doi:10.1089/neu.2008.0810. [PubMed: 19594385]
51. Ziemka-Nalecz M, Stanaszek L, Zalewska T. Oxygen-glucose deprivation promotes gliogenesis and microglia activation in organotypic hippocampal slice culture: involvement of metalloproteinases. *Acta Neurobiol Exp (Wars).* 2013; 73(1):130–142. [PubMed: 23595289]
52. Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, Tsirka SE, Maletic-Savatic M. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell.* 2010; 7(4):483–495. doi:10.1016/j.stem.2010.08.014. [PubMed: 20887954]
53. Belmadani A, Tran PB, Ren D, Miller RJ. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. *J Neurosci.* 2006; 26(12):3182–3191. doi:10.1523/JNEUROSCI.0156-06.2006. [PubMed: 16554469]
54. Avaliani N, Sorensen AT, Ledri M, Bengzon J, Koch P, Brustle O, Deisseroth K, Andersson M, Kokaia M. Optogenetics reveal delayed afferent synaptogenesis on grafted human-induced pluripotent stem cell-derived neural progenitors. *Stem Cells.* 2014; 32(12):3088–3098. doi:10.1002/stem.1823. [PubMed: 25183299]
55. Maisano X, Litvina E, Tagliatela S, Aaron GB, Grabel LB, Naegele JR. Differentiation and functional incorporation of embryonic stem cell-derived GABAergic interneurons in the dentate gyrus of mice with temporal lobe epilepsy. *J Neurosci.* 2012; 32(1):46–61. doi:10.1523/JNEUROSCI.2683-11.2012. [PubMed: 22219269]
56. Shetty AK, Rao MS, Hattiangady B. Behavior of hippocampal stem/progenitor cells following grafting into the injured aged hippocampus. *J Neurosci Res.* 2008; 86(14):3062–3074. doi:10.1002/jnr.21764. [PubMed: 18618674]
57. Morin-Brureau M, De Bock F, Lerner-Natoli M. Organotypic brain slices: a model to study the neurovascular unit micro-environment in epilepsies. *Fluids Barriers CNS.* 2013; 10(1):11. doi:10.1186/2045-8118-10-11. [PubMed: 23391266]
58. Zehendner CM, White R, Hedrich J, Luhmann HJ. A neurovascular blood-brain barrier in vitro model. *Methods Mol Biol.* 2014; 1135:403–413. doi:10.1007/978-1-4939-0320-7_33. [PubMed: 24510882]
59. Justine A, Paula P, Luce VE, Laurence R. Regional and time-dependent neuroprotective effect of hypothermia following oxygen-glucose deprivation. *Hippocampus.* 2014 doi:10.1002/hipo.22364.
60. Gregersen M, Lee DH, Gabatto P, Bickler PE. Limitations of mild, moderate, and profound Hypothermia in protecting developing hippocampal neurons after simulated ischemia. *Ther Hypothermia Temp Manag.* 2013; 3(4):178–188. doi:10.1089/ther.2013.0017. [PubMed: 24380031]
61. Montero M, Gonzalez B, Zimmer J. Immunotoxic depletion of microglia in mouse hippocampal slice cultures enhances ischemia-like neurodegeneration. *Brain Res.* 2009; 1291:140–152. doi:10.1016/j.brainres.2009.06.097. [PubMed: 19595678]
62. Neumann J, Gunzer M, Gutzeit HO, Ullrich O, Reymann KG, Dinkel K. Microglia provide neuroprotection after ischemia. *Faseb J.* 2006; 20(6):714–716. doi:10.1096/fj.05-4882fje. [PubMed: 16473887]
63. Hong J, Cho IH, Kwak KI, Suh EC, Seo J, Min HJ, Choi SY, Kim CH, Park SH, Jo EK, Lee S, Lee KE, Lee SJ. Microglial Toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death. *J Biol Chem.* 2010; 285(50):39447–39457. doi:10.1074/jbc.M110.132522. [PubMed: 20923777]
64. Kovacs R, Rabanus A, Otahal J, Patzak A, Kardos J, Albus K, Heinemann U, Kann O. Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and

- entorhinal cortex slices. *J Neurosci*. 2009; 29(26):8565–8577. doi:10.1523/JNEUROSCI.5698-08.2009. [PubMed: 19571147]
65. Peng Y, Zhang QL, Xu D, Wang YP, Qin XY. Small hairpin RNA interference of the Nogo receptor inhibits oxygen-glucose deprivation-induced damage in rat hippocampal slice cultures. *Neuropathology*. 2010; 30(6):565–573. doi:10.1111/j.1440-1789.2010.01102.x. [PubMed: 20337950]
 66. Norberg J, Poulsen FR, Blaabjerg M, Kristensen BW, Bonde C, Montero M, Meyer M, Gramsbergen JB, Zimmer J. Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. *Curr Drug Targets CNS Neurol Disord*. 2005; 4(4):435–452. [PubMed: 16101559]
 67. Pringle AK, Benham CD, Sim L, Kennedy J, Iannotti F, Sundstrom LE. Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. *Stroke*. 1996; 27(11):2124–2130. [PubMed: 8898826]
 68. Ray AM, Owen DE, Evans ML, Davis JB, Benham CD. Caspase inhibitors are functionally neuroprotective against oxygen glucose deprivation induced CA1 death in rat organotypic hippocampal slices. *Brain Res*. 2000; 867(1–2):62–69. [PubMed: 10837798]
 69. Cho S, Liu D, Fairman D, Li P, Jenkins L, McGonigle P, Wood A. Spatiotemporal evidence of apoptosis-mediated ischemic injury in organotypic hippocampal slice cultures. *Neurochem Int*. 2004; 45(1):117–127. doi:10.1016/j.neuint.2003.11.012. [PubMed: 15082229]
 70. Meli E, Pangallo M, Baronti R, Chiarugi A, Cozzi A, Pellegrini-Giampietro DE, Moroni F. Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage. *Toxicol Lett*. 2003; 139(2–3):153–162. [PubMed: 12628750]
 71. Laake JH, Haug FM, Wieloch T, Ottersen OP. A simple in vitro model of ischemia based on hippocampal slice cultures and propidium iodide fluorescence. *Brain Res Brain Res Protoc*. 1999; 4(2):173–184. [PubMed: 10446412]
 72. Runden E, Seglen PO, Haug FM, Ottersen OP, Wieloch T, Shamloo M, Laake JH. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase- dependent mechanism. *J Neurosci*. 1998; 18(18):7296–7305. [PubMed: 9736650]
 73. Moroni F, Formentini L, Gerace E, Camaioni E, Pellegrini-Giampietro DE, Chiarugi A, Pellicciari R. Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. *Br J Pharmacol*. 2009; 157(5):854–862. doi:10.1111/j.1476-5381.2009.00232.x. [PubMed: 19422384]
 74. Moroni F, Meli E, Peruginelli F, Chiarugi A, Cozzi A, Picca R, Romagnoli P, Pellicciari R, Pellegrini-Giampietro DE. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. *Cell Death Differ*. 2001; 8(9):921–932. doi:10.1038/sj.cdd.4400884. [PubMed: 11526447]
 75. Ohashi H, Maruyama T, Higashi-Matsumoto H, Nomoto T, Nishimura S, Takeuchi Y. A novel binding assay for metabotropic glutamate receptors using [3H] L-quisqualic acid and recombinant receptors. *Z Naturforsch C*. 2002; 57(3–4):348–355. [PubMed: 12064739]
 76. Bruce AJ, Sakhi S, Schreiber SS, Baudry M. Development of kainic acid and N-methyl-D-aspartic acid toxicity in organotypic hippocampal cultures. *Exp Neurol*. 1995; 132(2):209–219. [PubMed: 7540554]
 77. Kristensen BW, Norberg J, Thiebaud P, Koudelka-Hep M, Zimmer J. Biocompatibility of silicon-based arrays of electrodes coupled to organotypic hippocampal brain slice cultures. *Brain Res*. 2001; 896(1–2):1–17. [PubMed: 11277967]
 78. Rimvall K, Keller F, Waser PG. Selective kainic acid lesions in cultured explants of rat hippocampus. *Acta Neuropathol*. 1987; 74(2):183–190. [PubMed: 3673509]
 79. Jakobsen B, Tasker A, Zimmer J. Domoic acid neurotoxicity in hippocampal slice cultures. *Amino Acids*. 2002; 23(1–3):37–44. doi:10.1007/s00726-001-0107-5. [PubMed: 12373516]
 80. Holopainen IE, Jarvela J, Lopez-Picon FR, Pelliniemi LJ, Kukko-Lukjanov TK. Mechanisms of kainate-induced region-specific neuronal death in immature organotypic hippocampal slice cultures. *Neurochem Int*. 2004; 45(1):1–10. doi:10.1016/j.neuint.2004.01.005. [PubMed: 15082216]

81. Gatherer M, Sundstrom LE. Mossy fibre innervation is not required for the development of kainic acid toxicity in organotypic hippocampal slice cultures. *Neurosci Lett*. 1998; 253(2):119–122. [PubMed: 9774164]
82. Newell DW, Malouf AT, Franck JE. Glutamate-mediated selective vulnerability to ischemia is present in organotypic cultures of hippocampus. *Neurosci Lett*. 1990; 116(3):325–330. [PubMed: 1978744]
83. Vornov JJ, Tasker RC, Coyle JT. Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia. *Stroke*. 1994; 25(2):457–464. discussion 464–455. [PubMed: 8303757]
84. Barth A, Barth L, Morrison RS, Newell DW. bFGF enhances the protective effects of MK-801 against ischemic neuronal injury in vitro. *Neuroreport*. 1996; 7(9):1461–1464. [PubMed: 8856698]
85. Barth A, Barth L, Newell DW. Combination therapy with MK-801 and alpha-phenyltert-butyl-nitrone enhances protection against ischemic neuronal damage in organotypic hippocampal slice cultures. *Exp Neurol*. 1996; 141(2):330–336. doi:10.1006/exnr.1996.0168. [PubMed: 8812169]
86. Abdel-Hamid KM, Tymianski M. Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. *J Neurosci*. 1997; 17(10):3538–3553. [PubMed: 9133378]
87. Kristensen BW, Noraberg J, Zimmer J. Comparison of excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures. *Brain Res*. 2001; 917(1):21–44. [PubMed: 11602227]
88. Wahl P, Schousboe A, Honore T, Drejer J. Glutamate-induced increase in intracellular Ca²⁺ in cerebral cortex neurons is transient in immature cells but permanent in mature cells. *J Neurochem*. 1989; 53(4):1316–1319. [PubMed: 2570129]
89. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. *Nature*. 1991; 354(6348):31–37. doi: 10.1038/354031a0. [PubMed: 1834949]
90. Jonas P, Burnashev N. Molecular mechanisms controlling calcium entry through AMPA-type glutamate receptor channels. *Neuron*. 1995; 15(5):987–990. [PubMed: 7576666]
91. Sommer B, Keinänen K, Verdoorn TA, Wisden W, Burnashev N, Herb A, Kohler M, Takagi T, Sakmann B, Seeburg PH. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. *Science*. 1990; 249(4976):1580–1585. [PubMed: 1699275]
92. Bernard A, Ferhat L, Dessi F, Charton G, Represa A, Ben-Ari Y, Khrestchatsky M. Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for independent developmental, pathological and cellular regulation. *Eur J Neurosci*. 1999; 11(2):604–616. [PubMed: 10051761]
93. Wisden W, Seeburg PH. Mammalian ionotropic glutamate receptors. *Curr Opin Neurobiol*. 1993; 3(3):291–298. [PubMed: 8396474]
94. Tanabe M, Gahwiler BH, Gerber U. L-Type Ca²⁺ channels mediate the slow Ca²⁺-dependent afterhyperpolarization current in rat CA3 pyramidal cells in vitro. *J Neurophysiol*. 1998; 80(5):2268–2273. [PubMed: 9819242]
95. Budd SL. Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation. *Pharmacology & therapeutics*. 1998; 80(2):203–229. [PubMed: 9839772]
96. Vallee L, Fontaine M, Nuyts JP, Ricart G, Krivosic I, Divry P, Vianey-Saban C, Lhermitte M, Vamecq J. Stroke, hemiparesis and deficient mitochondrial beta-oxidation. *Eur J Pediatr*. 1994; 153(8):598–603. [PubMed: 7957409]
97. Rau TF, Lu Q, Sharma S, Sun X, Leary G, Beckman ML, Hou Y, Wainwright MS, Kavanaugh M, Poulsen DJ, Black SM. Oxygen glucose deprivation in rat hippocampal slice cultures results in alterations in carnitine homeostasis and mitochondrial dysfunction. *PLoS One*. 2012; 7(9):e40881. doi:10.1371/journal.pone.0040881. [PubMed: 22984394]
98. Li CT, Zhang WP, Lu YB, Fang SH, Yuan YM, Qi LL, Zhang LH, Huang XJ, Zhang L, Chen Z, Wei EQ. Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells. *J Neurosci Res*. 2009; 87(4):991–1001. doi:10.1002/jnr.21913. [PubMed: 18951527]

99. Behl C, Trapp T, Skutella T, Holsboer F. Protection against oxidative stress-induced neuronal cell death--a novel role for RU486. *Eur J Neurosci.* 1997; 9(5):912–920. [PubMed: 9182944]
100. McManus T, Sadgrove M, Pringle AK, Chad JE, Sundstrom LE. Intraischemic hypothermia reduces free radical production and protects against ischemic insults in cultured hippocampal slices. *J Neurochem.* 2004; 91(2):327–336. doi:10.1111/j.1471-4159.2004.02711.x. [PubMed: 15447666]
101. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischemic stroke: an integrated view. *Trends Neurosci.* 1999; 22(9):391–397. [PubMed: 10441299]
102. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. *Brain Res Rev.* 2007; 54(1):34–66. doi:10.1016/j.brainresrev.2006.11.003. [PubMed: 17222914]
103. Benakis C, Bonny C, Hirt L. JNK inhibition and inflammation after cerebral ischemia. *Brain Behav Immun.* 2010; 24(5):800–811. doi:10.1016/j.bbi.2009.11.001. [PubMed: 19903520]
104. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. *J Cereb Blood Flow Metab.* 1999; 19(8):819–834. [PubMed: 10458589]
105. del Zoppo GJ, Becker KJ, Hallenbeck JM. Inflammation after stroke: is it harmful? *Arch Neurol.* 2001; 58(4):669–672. [PubMed: 11296002]
106. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. *J Leukoc Biol.* 2006; 80(6):1298–1307. doi:10.1189/jlb.0406249. [PubMed: 16905575]
107. Leonardo CC, Hall AA, Collier LA, Gottschall PE, Pennypacker KR. Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. *Neuroscience.* 2009; 160(4):755–766. doi:10.1016/j.neuroscience.2009.02.080. [PubMed: 19272421]
108. Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. *J Neurochem.* 2003; 87(2):407–416. [PubMed: 14511118]
109. Yoshinaga H, Watanabe M, Manome Y. Possible role of nicaraven in neuroprotective effect on hippocampal slice culture. *Can J Physiol Pharmacol.* 2003; 81(7):683–689. doi:10.1139/y03-060. [PubMed: 12897815]
110. O'Dell TJ, Hawkins RD, Kandel ER, Arancio O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. *Proc Natl Acad Sci U S A.* 1991; 88(24):11285–11289. [PubMed: 1684863]
111. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. *Proc Natl Acad Sci U S A.* 2000; 97(5):2264–2269. doi:10.1073/pnas.040552897. [PubMed: 10681455]
112. Thevenet J, Angelillo-Scherrer A, Price M, Hirt L. Coagulation factor Xa activates thrombin in ischemic neural tissue. *J Neurochem.* 2009; 111(3):828–836. doi:10.1111/j.1471-4159.2009.06369.x. [PubMed: 19719823]
113. Mirante O, Price M, Puentes W, Castillo X, Benakis C, Thevenet J, Monard D, Hirt L. Endogenous protease nexin-1 protects against cerebral ischemia. *Int J Mol Sci.* 2013; 14(8):16719–16731. doi:10.3390/ijms140816719. [PubMed: 23949634]
114. Granziera C, Thevenet J, Price M, Wiegler K, Magistretti PJ, Badaut J, Hirt L. Thrombin-induced ischemic tolerance is prevented by inhibiting c-jun N-terminal kinase. *Brain Res.* 2007; 1148:217–225. doi:10.1016/j.brainres.2007.02.025. [PubMed: 17362885]
115. Coronado VG, Xu L, Basavaraju SV, McGuire LC, Wald MM, Faul MD, Guzman BR, Hemphill JD, Centers for Disease C, Prevention. Surveillance for traumatic brain injury-related deaths--United States, 1997–2007. *MMWR Surveill Summ.* 2011; 60(5):1–32. [PubMed: 21544045]
116. Ghajar J. Traumatic brain injury. *Lancet.* 2000; 356(9233):923–929. doi:10.1016/S0140-6736(00)02689-1. [PubMed: 11036909]
117. Di Pietro V, Amin D, Pernagallo S, Lazzarino G, Tavazzi B, Vagnozzi R, Pringle A, Belli A. Transcriptomics of traumatic brain injury: gene expression and molecular pathways of different grades of insult in a rat organotypic hippocampal culture model. *J Neurotrauma.* 2010; 27(2):349–359. doi:10.1089/neu.2009.1095. [PubMed: 19903084]

118. Coburn M, Maze M, Franks NP. The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. *Crit Care Med.* 2008; 36(2):588–595. doi:10.1097/01.CCM.0B013E3181611F8A6. [PubMed: 18216607]
119. Di Pietro V, Amorini AM, Tavazzi B, Hovda DA, Signoretti S, Giza CC, Lazzarino G, Vagnozzi R, Lazzarino G, Belli A. Potentially neuroprotective gene modulation in an in vitro model of mild traumatic brain injury. *Mol Cell Biochem.* 2013; 375(1–2):185–198. doi:10.1007/s11010-012-1541-2. [PubMed: 23242602]
120. Morrison B 3rd, Cater HL, Wang CC, Thomas FC, Hung CT, Ateshian GA, Sundstrom LE. A tissue level tolerance criterion for living brain developed with an in vitro model of traumatic mechanical loading. *Stapp Car Crash J.* 2003; 47:93–105. [PubMed: 17096246]
121. Morrison B 3rd, Cater HL, Benham CD, Sundstrom LE. An in vitro model of traumatic brain injury utilising two-dimensional stretch of organotypic hippocampal slice cultures. *J Neurosci Methods.* 2006; 150(2):192–201. doi:10.1016/j.jneumeth.2005.06.014. [PubMed: 16098599]
122. Cater HL, Sundstrom LE, Morrison B 3rd. Temporal development of hippocampal cell death is dependent on tissue strain but not strain rate. *J Biomech.* 2006; 39(15):2810–2818. doi:10.1016/j.jbiomech.2005.09.023. [PubMed: 16289515]
123. Elkin BS, Morrison B 3rd. Region-specific tolerance criteria for the living brain. *Stapp Car Crash J.* 2007; 51:127–138. [PubMed: 18278594]
124. Schoeler M, Loetscher PD, Rossaint R, Fahlenkamp AV, Eberhardt G, Rex S, Weis J, Coburn M. Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury. *BMC Neurol.* 2012; 12:20. doi:10.1186/1471-2377-12-20. [PubMed: 22494498]
125. Alexander MP. Mild traumatic brain injury: pathophysiology, natural history, and clinical management. *Neurology.* 1995; 45(7):1253–1260. [PubMed: 7617178]
126. Utagawa A, Bramlett HM, Daniels L, Lotocki G, Dekaban GA, Weaver LC, Dietrich WD. Transient blockage of the CD11d/CD18 integrin reduces contusion volume and macrophage infiltration after traumatic brain injury in rats. *Brain Res.* 2008; 1207:155–163. doi:10.1016/j.brainres.2008.02.057. [PubMed: 18374312]
127. Clausen F, Lorant T, Lewen A, Hillered L. T lymphocyte trafficking: a novel target for neuroprotection in traumatic brain injury. *J Neurotrauma.* 2007; 24(8):1295–1307. doi:10.1089/neu.2006.0258. [PubMed: 17711391]
128. Zhang Z, Zhang ZY, Wu Y, Schluesener HJ. Lesional accumulation of CD163+ macrophages/microglia in rat traumatic brain injury. *Brain Res.* 2012; 1461:102–110. doi:10.1016/j.brainres.2012.04.038. [PubMed: 22583855]
129. Fluiter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. *J Immunol.* 2014; 192(5):2339–2348. doi:10.4049/jimmunol.1302793. [PubMed: 24489093]
130. Bellander BM, Olafsson IH, Ghatan PH, Bro Skejo HP, Hansson LO, Wanecek M, Svensson MA. Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. *Acta Neurochir (Wien).* 2011; 153(1):90–100. doi:10.1007/s00701-010-0737-z. [PubMed: 20686797]
131. Bellander BM, Bendel O, Von Euler G, Ohlsson M, Svensson M. Activation of microglial cells and complement following traumatic injury in rat entorhinal-hippocampal slice cultures. *J Neurotrauma.* 2004; 21(5):605–615. doi:10.1089/089771504774129937. [PubMed: 15165368]
132. Smith SL, Andrus PK, Zhang JR, Hall ED. Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. *J Neurotrauma.* 1994; 11(4):393–404. [PubMed: 7837280]
133. Pacher P, Mackie K. Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration. *J Mol Med (Berl).* 2012; 90(4):347–351. doi:10.1007/s00109-012-0884-1. [PubMed: 22371074]
134. Mustafa AG, Singh IN, Wang J, Carrico KM, Hall ED. Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals. *J Neurochem.* 2010; 114(1):271–280. doi:10.1111/j.1471-4159.2010.06749.x. [PubMed: 20403083]

135. Singh IN, Gilmer LK, Miller DM, Cebak JE, Wang JA, Hall ED. Phenelzine mitochondrial functional preservation and neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal. *J Cereb Blood Flow Metab.* 2013; 33(4):593–599. doi:10.1038/jcbfm.2012.211. [PubMed: 23321786]
136. Long DA, Ghosh K, Moore AN, Dixon CE, Dash PK. Deferoxamine improves spatial memory performance following experimental brain injury in rats. *Brain Res.* 1996; 717(1–2):109–117. [PubMed: 8738260]
137. Huang Y, Huang X. Course of acute oxidative damage after traumatic brain injury: problem and strategy. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2014; 39(2):195–198. doi:10.11817/j.issn.1672-7347.2014.02.015. [PubMed: 24608393]
138. Avramescu S, Timofeev I. Synaptic strength modulation after cortical trauma: a role in epileptogenesis. *J Neurosci.* 2008; 28(27):6760–6772. doi:10.1523/JNEUROSCI.0643-08.2008. [PubMed: 18596152]
139. Annegers JF, Coan SP. The risks of epilepsy after traumatic brain injury. *Seizure.* 2000; 9(7):453–457. doi:10.1053/seiz.2000.0458. [PubMed: 11034867]
140. Kao C, Forbes JA, Jermakowicz WJ, Sun DA, Davis B, Zhu J, Lagrange AH, Konrad PE. Suppression of thalamocortical oscillations following traumatic brain injury in rats. *J Neurosurg.* 2012; 117(2):316–323. doi:10.3171/2012.4.JNS111170. [PubMed: 22631688]
141. McKinney RA, Debanne D, Gahwiler BH, Thompson SM. Lesion-induced axonal sprouting and hyperexcitability in the hippocampus in vitro: implications for the genesis of posttraumatic epilepsy. *Nat Med.* 1997; 3(9):990–996. [PubMed: 9288725]
142. Sun D, Bullock MR, Altememi N, Zhou Z, Hagood S, Rolfe A, McGinn MJ, Hamm R, Colello RJ. The effect of epidermal growth factor in the injured brain after trauma in rats. *J Neurotrauma.* 2010; 27(5):923–938. doi:10.1089/neu.2009.1209. [PubMed: 20158379]
143. Johanson C, Stopa E, Baird A, Sharma H. Traumatic brain injury and recovery mechanisms: peptide modulation of periventricular neurogenic regions by the choroid plexus-CSF nexus. *J Neural Transm.* 2011; 118(1):115–133. doi:10.1007/s00702-010-0498-0. [PubMed: 20936524]
144. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. *Neuroscience.* 1998; 82(1):129–137. [PubMed: 9483509]
145. Kurihara D, Yamashita T. Chondroitin sulfate proteoglycans down-regulate spine formation in cortical neurons by targeting tropomyosin-related kinase B (TrkB) protein. *J Biol Chem.* 2012; 287(17):13822–13828. doi:10.1074/jbc.M111.314070. [PubMed: 22389491]
146. Gill R, Chang PK, Prenosil GA, Deane EC, McKinney RA. Blocking brain-derived neurotrophic factor inhibits injury-induced hyperexcitability of hippocampal CA3 neurons. *Eur J Neurosci.* 2013; 38(11):3554–3566. doi:10.1111/ejn.12367. [PubMed: 24118418]
147. Daviaud N, Garbayo E, Schiller PC, Perez-Pinzon M, Montero-Menei CN. Organotypic cultures as tools for optimizing central nervous system cell therapies. *Exp Neurol.* 2013; 248:429–440. doi:10.1016/j.expneurol.2013.07.012. [PubMed: 23899655]
148. Lossi L, Alasia S, Salio C, Merighi A. Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS. *Prog Neurobiol.* 2009; 88(4):221–245. doi:10.1016/j.pneurobio.2009.01.002. [PubMed: 19552996]
149. de Almeida LM, Leite MC, Thomazi AP, Battu C, Nardin P, Tortorelli LS, Zanotto C, Posser T, Wofchuk ST, Leal RB, Goncalves CA, Gottfried C. Resveratrol protects against oxidative injury induced by H₂O₂ in acute hippocampal slice preparations from Wistar rats. *Arch Biochem Biophys.* 2008; 480(1):27–32. doi:10.1016/j.abb.2008.09.006. [PubMed: 18835240]
150. Mielke JG. Susceptibility to oxygen-glucose deprivation is reduced in acute hippocampal slices from euthermic Syrian golden hamsters relative to slices from Sprague-Dawley rats. *Neurosci Lett.* 2013; 553:13–17. doi:10.1016/j.neulet.2013.07.050. [PubMed: 23933209]
151. Sarntinoranont M, Lee SJ, Hong Y, King MA, Subhash G, Kwon J, Moore DF. High-strain-rate brain injury model using submerged acute rat brain tissue slices. *J Neurotrauma.* 2012; 29(2):418–429. doi:10.1089/neu.2011.1772. [PubMed: 21970544]

152. Takano T, He W, Han X, Wang F, Xu Q, Wang X, Oberheim Bush NA, Cruz N, Dienel GA, Nedergaard M. Rapid manifestation of reactive astrogliosis in acute hippocampal brain slices. *Glia*. 2014; 62(1):78–95. doi:10.1002/glia.22588. [PubMed: 24272704]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. The preparation and pathological models of chronic organotypic hippocampal slice cultures (OHSCs)

Hippocampus is dissected from mouse brains (from -1.06 mm to -2.80 mm relative to bregma) at postnatal day 3 to 9. OHSCs are prepared with a tissue chopper and are generally $350\text{ }\mu\text{m}$ in thickness. After being cultured for 10–14 days *in vitro* (DIV), the slices thin out and should have a healthy/integrated structure under brightfield microscopy. The disease models and pathophysiologic processes that can be studied with OHSCs are listed in the boxes. DG, dentate gyrus.